Franchise Group Inc (FRG)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or underway, with topline MG data expected in H1 2027. Competitive pressures from argenx, Amgen, and Novartis require VOR to demonstrate differentiated efficacy, safety, and physician trust for commercial success.
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety; the alternate fill-finish facility mitigates approval risk but does not eliminate it. SAPPHIRE trial data support apitegromab's add-on value in SMA, showing statistically significant motor function gains over placebo for nonambulatory patients.
Why Franchise Models Are Winning the Restaurant Stock Divide
Lower-income consumers have been pulling back on spending. But the impact on quick-service restaurant stocks hasn't been the same.
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise
Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 response rates and clean safety, with monthly dosing and efficacy across both biologic-experienced and naive patients. AVTX's $472M cash position secures operations into 2029, reducing near-term dilution risk and enhancing negotiating leverage for Phase 3 and beyond.
Redwood Trust: Legacy Losses Obscure A Profitable Mortgage Banking Franchise
Redwood Trust is rated Buy with a 12-month base case price target of $5.52, reflecting a 35% total return potential. RWT trades at a 33% discount to GAAP book value, as the market over-penalizes legacy asset risks despite strong core mortgage banking performance. Core platforms delivered a 33% annualized return on capital and robust volume growth, but legacy losses continue to drag on consolidated earnings and dividend coverage.
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise
Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials, with $436.1M in cash expected to last into 2H 2029, but it will likely need more capital before commercial launch. RAP-219's long half-life offers a 'forgiveness' advantage for missed doses, but regulatory scrutiny is expected regarding safety during prolonged exposure.
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise
Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM's pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while strong gross margins offer operating leverage.
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029, supporting multiple clinical catalysts across sutacimig, HMB-002, and preclinical HMB-003. Lead asset sutacimig shows strong Phase 2 efficacy and FDA-aligned Phase 3 dosing, while HMB-002 and HMB-003 broaden addressable markets.
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise
Zenas BioPharma (ZBIO) is positioned as more than a rare-disease play, leveraging obexelimab's B-cell inhibition platform for multiple autoimmune indications. ZBIO's Phase 3 INDIGO trial validates obexelimab in IgG4-RD, showing 56% flare reduction and improved safety versus placebo, supporting a differentiated mechanism. With $718.5M cash and milestone access, ZBIO expects runway through Q2 2029, enabling launch prep and expansion into SLE and MS indications.
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy
United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from currently approved products, providing a strong commercial base. Ralinepag and Nebulized Tyvaso in IPF are near-term pipeline catalysts, with multi-billion dollar peak sales potential if approved.
Arcos Dorados Provided Little Data On Its Franchise Agreement, The Name Is Not Attractive
Arcos Dorados' 4Q24 revenue declined due to FX headwinds, but comparable sales rose 1.7x inflation, indicating healthy demand despite macroeconomic challenges. Margins remain weak despite revenue growth, with EBITDA margin expanding only 40bps, highlighting high reinvestment needs and rising costs. The new Master Franchise Agreement with McDonald's lacks transparency, with key details on marketing and CAPEX requirements still undisclosed.
